Protein Markers. Clinical Chemistry 49: (2003) Proteomics and
|
|
- Anastasia McGee
- 5 years ago
- Views:
Transcription
1 Clinical Chemistry 49: (2003) Proteomics and Protein Markers Prognostic Value of Combination of Cardiac Troponin T and B-Type Natriuretic Peptide after Initiation of Treatment in Patients with Chronic Heart Failure Junnichi Ishii, 1* Wei Cui, 2 Fumihiko Kitagawa, 3 Takahiro Kuno, 3 Yuu Nakamura, 2 Hiroyuki Naruse, 2 Yoshihisa Mori, 2 Takashi Ishikawa, 3 Youichi Nagamura, 4 Takeshi Kondo, 2 Hisaji Oshima, 3 Masanori Nomura, 2 Kouji Ezaki, 2 and Hitoshi Hishida 2 Background: Recent studies have suggested that cardiac troponin T (ctnt) and troponin I may detect ongoing myocardial damage involved in the progression of chronic heart failure (CHF). This study was prospectively designed to examine whether the combination of ctnt, a marker for ongoing myocardial damage, and B-type natriuretic peptide (BNP), a marker for left ventricular overload, would effectively stratify patients with CHF after initiation of treatment. Methods: We measured serum ctnt, plasma BNP, and left ventricular ejection fraction (LVEF) on admission for worsening CHF [New York Heart Association (NYHA) functional class III to IV] and 2 months after initiation of treatment to stabilize CHF (n 100; mean age, 68 years). Results: Mean (SD) concentrations of ctnt [0.023 (0.066) vs (0.20) g/l] and BNP [249 (276) vs 753 (598) ng/l], percentage increased ctnt (>0.01 g/l; 35% vs 60%), NYHA functional class [2.5 (0.6) vs 3.5 (5)], and LVEF [43 (13)% vs 36 (12)%] were significantly (P <0.01) improved 2 months after treatment compared with admission. During a mean follow-up of 391 days, there 1 Division of Critical Care, Fujita Health University Graduate School of Health Sciences, 2 Department of Internal Medicine, Fujita Health University School of Medicine, 3 Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, and 4 Department of Clinical Chemistry, Fujita Health University School of Health Sciences, Toyoake , Japan. *Address correspondence to this author at: Division of Critical Care, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake , Japan. Fax ; jishii@fujita-hu.ac.jp. Received May 2, 2003; accepted August 28, DOI: /clinchem were 44 cardiac events, including 12 cardiac deaths and 32 readmissions for worsening CHF. On a stepwise Cox regression analysis, increased ctnt and BNP were independent predictors of cardiac events (P <0.001). ctnt >0.01 g/l and/or BNP >160 ng/l 2 months after initiation of treatment were associated with increased cardiac mortality and morbidity rates. Conclusion: The combination of ctnt and BNP measurements after initiation of treatment may be highly effective for risk stratification in patients with CHF American Association for Clinical Chemistry Serum concentrations of cardiac troponin T (ctnt) 5 and cardiac troponin I have been shown to be increased in patients with chronic heart failure (CHF) and to correlate with the severity of the disease and prognosis (1 7). These findings, coupled with the high cardiospecificity of both troponins (8, 9), suggest that ongoing myocardial damage plays an important role in the pathophysiology of CHF and can be documented by increases in cardiac troponins (1 7). The combination of ctnt, a marker for ongoing myocardial damage (1 4), and B-type natriuretic peptide (BNP), a marker for left ventricular overload (10, 11), might effectively stratify patients with CHF. Recently we measured ctnt and BNP concentrations on admission in 98 consecutive patients hospitalized for worsening CHF and monitored these individuals for adverse outcome 5 Nonstandard abbreviations: ctnt, cardiac troponin T; CHF, chronic heart failure; BNP, B-type natriuretic peptide; NYHA, New York Heart Association; ACS, acute coronary syndrome; LVEF, left ventricle ejection fraction; IHD, ischemic heart disease; and CI, confidence interval. 2020
2 Clinical Chemistry 49, No. 12, during a mean follow-up period of 451 days after admission. We showed that ctnt g/l and/or BNP 440 ng/l on admission could reliably stratify the patients into low-, intermediate-, and high-risk groups for cardiac mortality and morbidity (12). Accordingly, this study was prospectively designed to determine whether the combination of measuring ctnt and BNP concentrations after additional medical treatment for CHF could stratify patients with CHF. Materials and Methods We studied 100 consecutive patients, who had been admitted to Fujita Health University hospital for worsening CHF [New York Heart Association (NYHA) functional class III to IV] from June 1999 to June 2001, treated with standard oral drugs for 2 months after admission, and met none of the following criteria. Patients who had clinical or electrocardiographic evidence suggestive of acute coronary syndrome (ACS) for 2 months after treatment had been initiated were excluded from this study. Patients who underwent percutaneous coronary intervention or coronary artery bypass graft during the 2 months were excluded. Patients with a history of recent myocardial infarction or coronary revascularization (within 3 months of admission), myocarditis, renal failure (serum creatinine concentration 30 mg/l), or pulmonary disease were also excluded. Cardiologists not directly involved in this study determined whether patients met these exclusion criteria 2 months after admission. Informed consent was obtained from all patients before participation. Eight of the patients had been included in an earlier study (12). study protocol Venous blood samples were obtained for measurements of ctnt and BNP concentrations on admission and 2 months after treatment had been initiated to stabilize each patient s condition. At the same time, two-dimensional echocardiography was performed by experts blinded to the study, and left ventricular ejection fraction (LVEF) was calculated by use of the modified Simpson rule. All patients underwent clinical follow-up for a mean period of 391 days (range, days). Cardiac events, which were judged by researchers blinded to the biochemistry results, were defined as cardiac death (death from worsening CHF, fatal myocardial infarction, or sudden death) and readmission for worsening CHF or myocardial infarction. Myocardial infarction was defined by a combination of two of three characteristics: typical symptoms, time-dependent changes in serum creatine kinase MB activity, and a typical electrocardiographic pattern involving the development of Q waves. The diagnosis of worsening CHF was established by researchers blinded to biochemistry results on the basis of symptoms, physical findings, and evidence of pulmonary congestion on chest radiography. All patients who did not have a cardiac event underwent clinical follow-up for 12 months. Physicians blinded to the results of the biochemical tests independently selected the appropriate therapy and managed the patients according to standard protocols using outcome measures such as improvement in symptoms, physical findings, and evidence of pulmonary congestion on chest radiography (13). Diuretics were given in flexible dosages on the basis of body weight and daily diuresis. Spironolactone was administered as 25 or 50 mg/day. Angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, and beta-blocker were gradually increased to the maximum dosage possible for 2 months. The maximum dosages were 5 mg/day for enalapril, 5 mg/day for imidapril, 2 mg/day for temocapril, 50 mg/day for losartan, and 20 mg/day for carvedilol. measurements of biochemical markers Blood samples for measuring serum ctnt were centrifuged at 4 C for 15 min at 1000g and stored at 70 C until assayed. A third-generation Enzymun Test Troponin T assay was used, based on a prototype of the new electrochemiluminescence-based Elecsys system (Roche Diagnostics, Tokyo, Japan). The lower limit of detection of the assay for ctnt was 0.01 g/l. The imprecision for ctnt assay was 14% at g/l and 8.7% at g/l. ctnt was not detectable in 100 healthy adult volunteers. Blood samples for measuring plasma BNP were collected in chilled tubes containing EDTA, disodium salt, and aprotinin (500 IU/mL). The plasma was separated by centrifugation at 4 C for 15 min at 1000g and then stored at 70 C until analysis. BNP concentrations were measured by a commercial RIA for human BNP (Shiono RIA BNP assay; Shionogi Co., Ltd.). The lower limit of detection and the upper limit of the reference interval were 2 and 18.4 ng/l, respectively, for the BNP assay. The intraassay and interassay CV for BNP assay were 5.2% and 6.1%, respectively. data analysis Continuous variables were analyzed using the Mann Whitney U-test, Wilcoxon paired sign-rank test, or linear regression analysis, and the data are expressed as mean (SD). Values below the lower detection limit of the assay were defined as zero. Categorical variables were compared by the 2 test. Univariate and stepwise multivariate Cox regression analyses were used to evaluate the prognostic value of variables. Cardiac event-free survival was determined according to the Kaplan Meier method, and comparison of cardiac event-free survival between subgroups was performed using the log-rank test. ROC curves were used to determine the cutoff values of the biochemical markers for predicting cardiac events (14). P values 0.05 were considered significant.
3 2022 Ishii et al.: ctnt and BNP in Heart Failure Table 1. Comparison of demographics and clinical characteristics of 100 patients with CHF who did or did not die from a cardiac cause and did or did not have a cardiac event. All patients (n 100) No cardiac death (n 88) Cardiac death (n 12) No cardiac event (n 56) Cardiac event (n 44) Age, years 68 (11) 67 (10) 73 (10) a 66 (11) 71 (10) a Gender Male 56 (56%) 50 (57%) 6 (50%) 32 (57%) 24 (55%) Female 44 (44%) 38 (43%) 6 (50%) 24 (43%) 20 (45%) Etiology IHD 37 (37%) 32 (36%) 5 (42%) 17 (30%) 20 (45%) Non-IHD 63 (63%) 56 (64%) 7 (58%) 39 (70%) 24 (55%) Admission/2 months 2 months 2 months 2 months 2 months NYHA class 3.5 (0.5)/2.5 (0.6) b 2.4 (0.5) 2.8 (0.6) a 2.3 (0.4) 2.7 (0.6) b LVEF, % 36 (12)/43 (13) b 44 (13) 34 (10) a 47 (12) 38 (13) b Creatinine, mg/l 11.2 (5.2)/12.1 (5.3) a 11.3 (4.6) 16.3 (6.8) b 10.6 (3.9) 13.5 (6.1) b ctnt, g/l (0.20)/0.023 (0.066) b (0.007) (0.047) b (0.015) (0.094) b (Reference values 0.01 g/l) BNP, ng/l 753 (598)/249 (276) b 225 (268) 426 (279) b 141 (158) 386 (329) b (Reference values 18.4 ng/l) Treatment Diuretics 72/91 81 (92%) 10 (83%) 50 (89%) 41 (93%) Spironolactone 34/94 83 (94%) 11 (92%) 53 (95%) 41 (93%) ACE c inhibitors and/or ARBS 70/ (100%) 12 (100%) 56 (100%) 44 (100%) -Blockers 24/54 48 (55%) 6 (50%) 30 (54%) 24 (55%) a,b Versus admission values, no cardiac death, or no cardiac event: a P 0.05; b P c ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker. Results Patient characteristics are shown in Table 1. The severity of CHF on admission was NYHA functional class III in 54 patients and class IV in 46 patients. The severity of CHF 2 months after additional treatment was NYHA class II in 57 patients, class III in 40 patients, and class IV in 3 patients. The etiologies of CHF were ischemic heart disease (IHD) in 37 patients, hypertensive heart disease in 28 patients, aortic and/or mitral valve disease in 18 patients, dilated cardiomyopathy in 14 patients, atrial fibrillation with rapid ventricular response in 2 patients, and congenital heart disease in 1 patient. Follow-up was complete in all study patients. During the follow-up period, there were 2 noncardiac deaths (1 gastric cancer and 1 pneumonia) and 44 (44%) cardiac events, including 12 cardiac deaths and 32 readmissions for worsening CHF. The causes of cardiac death were worsening CHF in 9 patients and sudden death in 3 patients. At 2 months after the start of treatment, ctnt and BNP concentrations, NYHA functional class, and LVEF were significantly better than at the time of admission (Table 1). The percentage of increased ctnt ( 0.01 g/l) was significantly decreased at 2 months compared with on admission (35% vs 60%; P 0.001). At 2 months after treatment, ctnt was detectable in 11 (19%) of 57 patients in NYHA class II and in 24 (56%) of 43 patients in NYHA class III or class IV. There was a significant but weak correlation between ctnt and log BNP concentrations 2 months after initiation of treatment (r 0.24; P 0.05). Patients who died from a cardiac cause were older (P 0.05); had higher concentrations of ctnt, BNP, and creatinine (P 0.01); had a higher NYHA class (P 0.05); and had a lower LVEF (P 0.05) after treatment was established compared with those who did not die from a cardiac cause (Table 1). Patients who had a cardiac event were older (P 0.05); had higher concentrations of ctnt, BNP, and creatinine (P 0.01); had a higher NYHA class (P 0.01); and had a lower LVEF (P 0.01) after establishment of treatment (Table 1). However, the number of patients with IHD and the treatment regimens were similar in the two groups. The areas under the ROC curves for ctnt and BNP after treatment was initiated [0.73; 95% confidence interval (CI), for ctnt; 0.72; 95% CI, for BNP] did not differ significantly from each other (Fig. 1). The optimal values of ctnt and BNP for predicting cardiac events were defined as the concentration with the largest sum of sensitivity plus specificity for each of the curves; for ctnt, the optimal concentration was 0.01 g/l, and for BNP, it was 160 ng/l. The sensitivity, specificity, positive and negative predictive values, and overall accuracy for predicting cardiac death and cardiac events in patients with a serum ctnt 0.01 g/l were 100% (12 of 12) and 61% (27 of 44), 74% (65 of 88) and 86% (48 of 56), 34% (12 of 35) and 77% (27 of 35), 100% (65 of
4 Clinical Chemistry 49, No. 12, Fig. 1. ROC curves for troponin T (A) and BNP (B) 2 months after initiation of treatment in 100 patients with CHF who did and did not suffer a cardiac event. AUC, area under the curve. 65) and 74% (48 of 65), and 77% (77 of 100) and 75% (75 of 100), respectively. The corresponding sensitivity, specificity, positive and negative predictive values, and overall accuracy in patients with a plasma BNP 160 ng/l were 83% (10 of 12) and 73% (32 of 44), 57% (50 of 88) and 71% (40 of 56), 21% (10 of 48) and 67% (32 of 48), 96% (50 of 52) and 77% (40 of 52), and 60% (60 of 100) and 72% (72 of 100), respectively. The univariate and multivariate predictors of cardiac event and cardiac death are summarized in Table 2. On a stepwise Cox regression analysis including age, sex, etiology, NYHA class, LVEF, creatinine, ctnt, and BNP, only ctnt (P ) and BNP (P ) concentrations after treatment were independent predictors of cardiac events. In addition, when ctnt 0.01 g/l and BNP 160 ng/l after treatment were included in a Table 2. Univariate and multivariate predictors of cardiac death and cardiac events in patients 2 months after initiation of treatment for CHF. Variables Hazard ratio 95% CI P Univariate model of cardiac death and cardiac event Cardiac death Age (increase of 10 years) Gender (male 1) NS a Etiology (IHD 1) NS NYHA class LVEF (increase of 10%) Creatinine (increase of 10 mg/l) ctnt (increase of 0.1 g/l) Log BNP (10-fold increase) Cardiac event Age (increase of 10 years) Gender (male 1) NS Etiology (IHD 1) NYHA class LVEF (increase of 10%) Creatinine (increase of 10 mg/l) ctnt (increase of 0.1 g/l) Log BNP (10-fold increase) Multivariate model of cardiac event Multivariate model including ctnt and BNP concentrations ctnt (increase of 0.1 g/l) Log BNP (10-fold increase) LVEF (increase of 10%) Multivariate model including ctnt 0.01 g/l and BNP 160 ng/l as continuous variables ctnt 0.01 g/l BNP 160 ng/l LVEF (increase of 10%) a NS, not significant.
5 2024 Ishii et al.: ctnt and BNP in Heart Failure multivariate model as continuous variables, ctnt 0.01 g/l (P ) and BNP 160 ng/l (P 0.013) were independent predictors of cardiac events. A ctnt concentration 0.01 g/l and/or BNP 160 ng/l 2 months after initiation of treatment correlated with an incremental increase in cardiac mortality and cardiac morbidity rates (Fig. 2). With this combination, patients with or without BNP 160 ng/l could be further classified into two different risk groups for cardiac events (group II vs group IV, P 0.01; group I vs group III, P 0.1) and cardiac death (group II vs group IV, P 0.01; group I vs group III, P 0.05). In addition, patients with or without ctnt 0.01 g/l could be further classified into two different risk groups for cardiac event (group III vs group IV, P 0.1; group I vs group II, P 0.1). Thus the combination of ctnt and BNP concentrations after additional treatment appeared to improve the ability to stratify risk in patients with CHF over the individual use of these markers, especially BNP alone. Kaplan Meier analysis showed that this combination could be used to stratify the patients into the four groups for cardiac events (Fig. 3). Fig. 3. Cardiac event-free survival curves for the four risk groups of patients with CHF, based on ctnt and BNP concentrations 2 months after initiation of treatment. Group I, ctnt 0.01 g/l and BNP 160 ng/l; group II, ctnt 0.01 g/l and BNP 160 ng/l; group III, ctnt 0.01 g/l and BNP 160 ng/l; and group IV, ctnt 0.01 g/l and BNP 160 ng/l. Discussion The present study demonstrates that, similar to BNP concentrations (10, 11, 15, 16), ctnt concentrations after treatment is initiated are independently associated with cardiac events in patients with CHF and that a ctnt 0.01 g/l and/or BNP 160 ng/l after initiation of treatment could stratify patients into four groups for cardiac mortality and morbidity. Thus the combination of measuring ctnt, a marker for ongoing myocardial damage, and BNP, a marker for left ventricular overload, represents a highly effective means of risk stratification after additional medical treatment even in clinically stabilized CHF patients. Serum ctnt after treatment was initiated decreased in parallel with the decrease in BNP concentrations, improvement in LVEF, and symptom reduction, suggesting that ongoing myocardial damage may be partly suppressed by the treatment of CHF. Serum ctnt was still measurable 2 months after initiation of treatment in 35% of clinically stable patients with CHF. Such patients were at increased risk for cardiac death and cardiac events. ctnt was detectable after treatment was begun in all 12 patients who died of a cardiac death, and the ctnt concentration after initiation of treatment was an independent predictor of cardiac morbidity. These findings suggested that ongoing myocardial damage may play an important role in the progression of CHF and lead to an adverse outcome (1 7). In the present study, the combination of ctnt and BNP after treatment was able to stratify these clinically stable patients into four groups for adverse outcomes. The weak correlation between ctnt and BNP concentrations suggests that markers specific for ongoing myocardial dam- Fig. 2. Cardiac mortality (A) and cardiac event rates (B) for the four risk groups of patients with CHF, based on ctnt and BNP concentrations 2 months after initiation of treatment. Group I, ctnt 0.01 g/l and BNP 160 ng/l; group II, ctnt 0.01 g/l and BNP 160 ng/l; group III, ctnt 0.01 g/l and BNP 160 ng/l; group IV, ctnt 0.01 g/l and BNP 160 ng/l.
6 Clinical Chemistry 49, No. 12, age and left ventricular overload reflect different aspects of the pathophysiology of CHF and may identify different groups of patients at risk. It is reasonable to expect that patients who have both ongoing myocardial damage and left ventricular overload are at greatest risk. The authors of a recent study reported that aminoterminal probnp-guided treatment of heart failure reduced total cardiovascular events and delayed time to first event compared with intensive clinically guided treatment (17). In the present study, the combination of ctnt and BNP concentrations after additional treatment appeared to improve the ability to stratify risk in patients with CHF over the use of these markers individually, particularly BNP alone. Thus, our results indicate that the combination of ctnt and BNP might be used to guide the treatment of patients with CHF. When patients are categorized as group II or especially IV after additional treatment, further treatment and intensive care might improve the prognosis. When patients are rated as group III after additional treatment, even in the absence of high concentrations of BNP, further treatment to decrease the ctnt concentrations might be needed to reduce cardiac events. Additional studies are needed before treatment decisions can be based on these measurements. The multivariate analysis showed that LVEF tended to be an independent predictor of cardiac events. These findings indicate that combinations of LVEF and ctnt, LVEF and BNP, or of both biochemical markers together with LVEF might effectively stratify patients with CHF. Further studies are needed to clarify the utility of these combinations in patients with CHF. It is difficult to completely exclude the possibility that increased concentrations of BNP and, particularly, ctnt might be related to ischemic cell injury attributable to ACS. We therefore investigated the association of adverse outcome with these markers 2 months after initiation of treatment, when patients were in stable clinical condition. We also ruled out patients who had clinical or electrocardiographic evidence suggestive of ACS or those who received coronary revascularization for 2 months after the initiation of treatment. We believe that this strategy can minimize the possibility that increased concentrations of these markers after treatment are caused by ischemic cell injury attributable to ACS. Recent studies have shown that increased concentrations of ctnt (18 21) and BNP (22, 23) may be independently associated with poor prognosis in patients undergoing chronic hemodialysis. It would be interesting to determine whether our findings might apply to patients with severe renal failure. However, to minimize the effects of renal clearance, we excluded patients with serum creatinine concentrations 30 mg/l. In the present study, there was a relatively small number of cardiac events (n 44) for every putative predictor (n 8) included in multivariate models. In addition, we could not use multivariate models to determine independent predictors of cardiac mortality because of the low number of cardiac deaths (n 12). Thus, additional studies should be carried out in a larger CHF population to confirm our results. Threshold values derived from the ROC curves are highly dependent on the study population and might have been different in another set of patients. Thus, the threshold values for ctnt and BNP that were used in the present study should be confirmed in larger follow-up studies. In addition, in the present study treatments were not randomized. Thus, it was difficult to evaluate the effects of specific drugs for CHF on adverse outcomes. In conclusion, the combination of ctnt and BNP measurements after initiation of treatment may be highly effective for risk stratification in patients with CHF. We would like to thank Roche Diagnostics for providing the required reagents and instruments. References 1. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J 1999;138: Del Carlo CH, O Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999;138: Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84: Setsuta K, Seino Y, Ogawa T, Arao M, Miyatake Y, Takano T. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 2002;113: Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96: La Vecchia L, Mezzena G, Ometto R, Finocchi G, Bedogni F, Soffiati G, et al. Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol 1997;80: La Vecchia L, Mezzena G, Zanolla L, Paccanaro M, Varotto L, Bonanno C, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000;19: Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, et al. Diagnostic efficacy of troponin T measurements in acute myocardial infarction. Circulation 1991;83: Adams JE 3rd, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993;88: Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96: Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135: Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89: Committee on Evaluation and Management of Heart Failure.
7 2026 Ishii et al.: ctnt and BNP in Heart Failure Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 1995; 92: Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36: Richards AM, Doughty R, Nicholls MG, MacMahon S, Ikram H, Sharpe N, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999;99: Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355: Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, et al. Cardiac troponin T predicts mortality in patients with end stage renal disease. Circulation 2000;102: Ooi DS, Zimmerman D, Graham J, Wells GA. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 2001;47: Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 2001;312: Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106: Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, et al., for Creed Investigators. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12: Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002;22:
Comparison with plasma angiotensin II and endothelin-1
European Heart Journal (1999) 2, 1799 187 Article No. euhj.1999.1746, available online at http://www.idealibrary.com on Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationSerum Heart-Type Fatty Acid Binding Protein Predicts Cardiac Events in Elderly Patients With Chronic Heart Failure
Serum Heart-Type Fatty Acid Binding Protein Predicts Cardiac Events in Elderly Patients With Chronic Heart Failure Takeshi Yasuchika Takanori Hidenobu Noriaki Hidetada Naoki Osamu Yuichi Takehiko Akio
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationThe clinical value of natriuretic peptide testing in heart failure
The clinical value of natriuretic peptide testing in heart failure James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Roman W. DeSanctis Endowed Clinical Scholar
More informationB-Type Natriuretic Peptide Predicts Future Cardiac Events in Patients Presenting to the Emergency Department With Dyspnea
ORIGINAL CONTRIBUTION B-Type Natriuretic Peptide Predicts Future Cardiac Events in Patients Presenting to the Emergency Department With Dyspnea From the Division of Cardiology and General Internal Medicine
More informationPrognostic Value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation
Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation Hidekazu Tsuneoka 1)2), Akira Koike 2), Osamu Nagayama 2), Koji Sakurada 2), Hitoshi Sawada 2), Kazutaka Aonuma
More informationFattori condizionanti la sopravvivenza nel paziente con scompenso di cuore
Journal Club 13 Febbraio 2008 Fattori condizionanti la sopravvivenza nel paziente con scompenso di cuore Intissar Sleiman Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationNT-proBNP A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure
Reference Section NT-proBNP A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure a report by Drs Rahul Sakhuja and James L Januzzi Cardiology Division and Department of Medicine,
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationPrognostic Value of Myocardial Damage Markers in Patients with Chronic Heart Failure with Atrial Fibrillation
ORIGINAL ARTICLE Prognostic Value of Myocardial Damage Markers in Patients with Chronic Heart Failure with Atrial Fibrillation Yoichiro Otaki, Takanori Arimoto, Hiroki Takahashi, Shinpei Kadowaki, Daisuke
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationRandomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure (J-CHF) Study
82th AHA Meeting Nov 17, 2009 Orlando, USA Presenter Disclosure Information Randomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationArbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationRehospitalization Prognostic Factors in Patients with Heart Failure: a Prospective Follow-up Study
ARC Journal of Cardiology Volume2, Issue 2, 2016, PP 13-18 ISSN No. (Online) 2455-5991 http://dx.doi.org/10.20431/2455-5991.0202002 www.arcjournals.org Rehospitalization Prognostic Factors in Patients
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationThe Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients
The Journal of International Medical Research 2003; 31: 76 83 The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationT he incidence of congestive heart failure (CHF) has
1303 CARDIOVASCULAR MEDICINE Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure T Goto, H Takase, T Toriyama, T Sugiura, K Sato, R Ueda, Y Dohi... See end
More informationPlasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice
Journal of Cardiology (2008) 52, 212 223 ORIGINAL ARTICLE Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice Keizo Tsuchida (MD) a,, Kazuhiko
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationChronic heart failure (CHF) is a major cause of morbidity
Systolic Blood Pressure Response to Exercise as a Predictor of Mortality in Patients With Chronic Heart Failure Yasuhiro Nishiyama, 1 MD, Hirohiko Morita, 1 MD, Haruhito Harada, 1 MD, Atsushi Katoh, 1
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationESCBM meeting 2018, Prague Utility of Cardiac Biomarkers in Clinical Heart Failure Care. Md. Shahidul Islam, M.D., Ph.D
ESCBM meeting 2018, Prague Utility of Cardiac Biomarkers in Clinical Heart Failure Care Md. Shahidul Islam, M.D., Ph.D shaisl@me.com 2 3 Circulating Biomarkers in Heart Failure. Berezin AE. Adv. Exp. Med.
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationInfluence of Paroxysmal Atrial Fibrillation Attack on Brain Natriuretic Peptide Secretion
Influence of Paroxysmal Atrial Fibrillation Attack on Brain Natriuretic Peptide Secretion Keizo Kazuhiko TSUCHIDA,MD TANABE, MD Abstract Objectives. Plasma brain natriuretic peptide BNP concentration is
More informationSupplementary Online Content
Supplementary Online Content Nikolova AP, Hitzeman TC, Baum R, et al. Association of a novel diagnostic biomarker, the plasma cardiac bridging integrator 1 score, with heart failure with preserved ejection
More informationSerum Cardiac Troponin T in Cardiac Amyloidosis: Serial Observations in Five Patients
Tohoku J. Exp. Med., 2006, 208, 163-167 ctnt in Cardiac Amyloidosis 163 Serum Cardiac Troponin T in Cardiac Amyloidosis: Serial Observations in Five Patients Case Report TAKAO KATO, YUKIHITO SATO, KAZUYA
More informationIntroduction. Key words: cardiac biomarkers; short-term mortality; perioperative risk; non-cardiac surgery; coronary artery disease
ISSN 2466-488X (Online) doi:10.5937/sjait1806117j Original work PREOPERATIVE HIGH-SENSITIVE TROPONIN T AND N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE IN PREDICTION OF SHORT-TERM MORTALITY AFTER NON-CARDIAC
More informationClinical Investigations
Clinical Investigations Predictors of 30-Day Readmission in Patients Hospitalized With Decompensated Heart Failure Address for correspondence: Gian M. Novaro, MD, Department of Cardiology, Cleveland Clinic
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationCARDIOVASCULAR N-terminal pro-b-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study
CARDIOVASCULAR N-terminal pro-b-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study B. H. Cuthbertson 1 *, B. L. Croal 2, D. Rae 1, P. H. Gibson 3, J. D.
More informationHeart failure (HF) is a disabling condition with high
N-Terminal Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients Paulo Bettencourt, PhD; Ana Azevedo, MD; Joana Pimenta, MD; Fernando Friões, MD; Susana Ferreira,
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationSCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA
Journal Club 19 Marzo 2010 SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA Alessandro Giordano Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007 Incidence of heart failure by age
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationPrediction of Mortality by High-Sensitivity C-Reactive Protein and Brain Natriuretic Peptide in Patients With Dilated Cardiomyopathy
Circ J 6; 7: 87 863 Prediction of Mortality by High-Sensitivity C-Reactive Protein and Brain Natriuretic Peptide in Patients With Dilated Cardiomyopathy Chitose Ishikawa, MD; Takayoshi Tsutamoto, MD; Masanori
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationVitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0.
ALDOSTERONE ANTAGONIST IN HEART FAILURE WITH PRESERVED EJECTION FRACTION ABBREVIATIONS BMP: basic metabolic panel HPI: history of present illness CAD: coronary artery disease HR: heart rate PINHUI (JUDY)
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationDisclosure Information : No conflict of interest
Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationJournal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.035
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationRight Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa
Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa 1 Ojji Dike B, Lecour Sandrine, Atherton John J, Blauwet Lori A, Alfa Jacob, Sliwa
More informationImpact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction
doi: 10.2169/internalmedicine.8510-16 http://internmed.jp ORIGINAL ARTICLE Impact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction Taro Ichise, Hayato
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationThe Effects of Ranitidine in Chronic Heart Failure Patients
Keerati Hantrakool, MD, and Jarkarpun Chaipromprasit, MD. Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Abstract Objectives: To determine
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationChronic heart failure (CHF) is a complex syndrome that
Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure The Bio-SHiFT Study Elke Bouwens, MD;* Milos Brankovic, MD, PhD;*
More informationLong-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure
Long-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure Naomi Naoki Yoko Yoshie Hiroshi KAWASHIRO, MD MATSUDA, MD ENDO, MD UCHIDA, MD KASANUKI, MD, FJCC
More information*Christian M. Carlsen, 1 Mette Mouridsen, 1 Ahmad Sajadieh, 1 Lars Køber, 2 Olav W. Nielsen 1 ABSTRACT BACKGROUND
USE OF N-TERMINAL NATRIURETIC PEPTIDE IN A REAL- WORLD SETTING OF PATIENTS ADMITTED WITH ACUTE DYSPNOEA AND THE IMPLICATION FOR TRIAGING PATIENTS IN THE EMERGENCY DEPARTMENT *Christian M. Carlsen, 1 Mette
More informationRelationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction
European Heart Journal (2003) 24, 346 355 Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction T. Tsutamoto
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationCan point of care cardiac biomarker testing guide cardiac safety during oncology trials?
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University
More informationRita Calé, Miguel Mendes, António Ferreira, João Brito, Pedro Sousa, Pedro Carmo, Francisco Costa, Pedro Adragão, João Calqueiro, José Aniceto Silva.
Peak Circulatory Power : a new parameter of cardiopulmonary exercise testing to predict arrhythmic events in patients with implantable cardioverter defibrillator for primary prevention Rita Calé, Miguel
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationBNP as a Predictor of Cardiovascular Disease and All Cause Mortality. Dr. Thierry Le Jemtel
BNP as a Predictor of Cardiovascular Disease and All Cause Mortality Dr. Thierry Le Jemtel Outline Role of BNP and probnp as relevant biomarkers in cardiac conditions Role of BNP and probnp as relevant
More informationChapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationEvaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography
Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography Rebecka Karlsson Pardeep Jhund 1 Material and methods
More informationN-terminal Pro B-type Natriuretic Peptide Predicts Cardiac Events in Discharged Patients with Idiopathic Dilated Cardiomyopathy
Original ORIGINAL Article ARTICLE Korean Circulation J 2007;37:202-207 ISSN 1738-5520 c 2007, The Korean Society of Circulation N-terminal Pro B-type Natriuretic Peptide Predicts Cardiac Events in Discharged
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More information